BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 19002577)

  • 1. Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha.
    Lam L; Hu X; Aktary Z; Andrews DW; Pasdar M
    Breast Cancer Res Treat; 2009 Dec; 118(3):605-21. PubMed ID: 19002577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780.
    Chan TW; Pollak M; Huynh H
    Clin Cancer Res; 2001 Aug; 7(8):2545-54. PubMed ID: 11489838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiestrogen ICI 182,780 decreases proliferation of insulin-like growth factor I (IGF-I)-treated MCF-7 cells without inhibiting IGF-I signaling.
    Varma H; Conrad SE
    Cancer Res; 2002 Jul; 62(14):3985-91. PubMed ID: 12124331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
    J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.
    Zhang Y; Moerkens M; Ramaiahgari S; de Bont H; Price L; Meerman J; van de Water B
    Breast Cancer Res; 2011 May; 13(3):R52. PubMed ID: 21595894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor binding protein-4 and -5 modulate ligand-dependent estrogen receptor-α activation in breast cancer cells in an IGF-independent manner.
    Hermani A; Shukla A; Medunjanin S; Werner H; Mayer D
    Cell Signal; 2013 Jun; 25(6):1395-402. PubMed ID: 23499909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor alpha (ERalpha) and insulin-like growth factor I receptor (IGF-IR) cross-talk in the gonadotropic alphaT3-1 cell line.
    Eertmans F; Dhooge W; De Wever O; Bracke M; Comhaire F; Kaufman JM
    J Cell Physiol; 2007 Sep; 212(3):583-90. PubMed ID: 17458895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.
    Frogne T; Jepsen JS; Larsen SS; Fog CK; Brockdorff BL; Lykkesfeldt AE
    Endocr Relat Cancer; 2005 Sep; 12(3):599-614. PubMed ID: 16172194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
    Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
    Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells.
    Lee YR; Park J; Yu HN; Kim JS; Youn HJ; Jung SH
    Biochem Biophys Res Commun; 2005 Nov; 336(4):1221-6. PubMed ID: 16169518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha.
    Brockdorff BL; Heiberg I; Lykkesfeldt AE
    Endocr Relat Cancer; 2003 Dec; 10(4):579-90. PubMed ID: 14713268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance.
    Louie MC; McClellan A; Siewit C; Kawabata L
    Mol Cancer Res; 2010 Mar; 8(3):343-52. PubMed ID: 20215421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells.
    Horner-Glister E; Maleki-Dizaji M; Guerin CJ; Johnson SM; Styles J; White IN
    J Mol Endocrinol; 2005 Dec; 35(3):421-32. PubMed ID: 16326830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hexachlorobenzene induces cell proliferation and IGF-I signaling pathway in an estrogen receptor alpha-dependent manner in MCF-7 breast cancer cell line.
    García MA; Peña D; Alvarez L; Cocca C; Pontillo C; Bergoc R; de Pisarev DK; Randi A
    Toxicol Lett; 2010 Feb; 192(2):195-205. PubMed ID: 19879930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668.
    Fog CK; Christensen IJ; Lykkesfeldt AE
    Breast Cancer Res Treat; 2005 May; 91(2):133-44. PubMed ID: 15868441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines.
    Treeck O; Haldar C; Ortmann O
    Oncol Rep; 2006 Jan; 15(1):231-5. PubMed ID: 16328061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-genomic actions of estradiol and 4-OH-tamoxifen on murine breast cancer cells.
    Raffo D; Pontiggia O; Bal de Kier Joffé E; Simian M
    Oncol Rep; 2015 Jan; 33(1):439-47. PubMed ID: 25338647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.